Table 2.
Patient characteristics used in this study.
| Characteristics | Entire cohort (n=480) |
Training set (n=432) |
Test set (n=48) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Age, median (range) | 67 (27 – 89) | 67 (27 – 89) | 65 (31 - 84) |
| Sex | |||
| Female | 182 (37,91%) | 162 (37,5%) | 20 (41,66%) |
| Male | 298 (62,09%) | 270 (62,5%) | 28 (58,33%) |
| Treatment | |||
| IO | 407 (84,79%) | 366 (84,72%) | 41 (85,41%) |
| IO/CT | 73 (15,21) | 66 (15,28%) | 7 (14.58%) |
| Histology | |||
| Non-Squamous | 384 (80%) | 342 (79.16%) | 42 (87,5%) |
| Squamous | 96 (20%) | 90 (20.84%) | 6 (12,5%) |
| ECOG performance status | |||
| ECOG 0 | 160 (33,33%) | 146 (33,79%) | 14 (29,16%) |
| ECOG 1 | 253 (52,71%) | 229 (53,01%) | 24 (50%) |
| ECOG ≥2 | 67 (13,95%) | 57 (13,19%) | 10 (20,83%) |
| PD-L1 expression | |||
| <1 | 119 (24,79%) | 109 (23,14%) | 10 (20,83%) |
| 1-49 | 135 (28,12%) | 124 (28,70%) | 11 (22,92%) |
| ≥50 | 110 (22,91%) | 97 (22,47%) | 13 (27,08%) |
| DCR | |||
| Class 0 (PD) | 233 (48,54%) | 210 (48,66%) | 23 (47,91%) |
| Class 1 (CR/PR/SD) | 247 (51,45%) | 222 (51,34%) | 25 (52,08%) |
| OS6 | |||
| Class 0 (<6month) | 195 (40,62%) | 173 (40,04%) | 22 (45,83%) |
| Class 1 (≥6months) | 285 (59,37%) | 259 (59,96%) | 26 (54,17%) |
| PFS | |||
| Class 0 (<3month) | 234 (48,75%) | 210 (43,75%) | 24 (50%) |
| Class 1 (≥3months) | 246 (51,25%) | 222 (56,25%) | 24 (50%) |